Results 141 to 150 of about 60,209 (283)

Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia

open access: yes
American Journal of Hematology, Volume 100, Issue 5, Page 909-912, May 2025.
Marcos de Lima   +14 more
wiley   +1 more source

A Phase I Study Evaluating Safety and Tolerability of Viral‐Specific T Cells Against BK‐Virus in Adult Kidney Transplant Recipients

open access: yesJournal of Medical Virology, Volume 97, Issue 4, April 2025.
ABSTRACT BK polyomavirus (BKPyV) poses a significant threat to kidney transplant recipients (KTR). Current management primarily involves reducing immunosuppression, which increases the risk of rejection. Cell‐based immunotherapy with virus‐specific T cells (VST) has emerged as an alternative approach for treating BKPyV in KTRs. This single‐center phase
Lucy Ptak   +8 more
wiley   +1 more source

SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION

open access: bronze, 1999
Carl G. Groth   +12 more
openalex   +1 more source

Cutaneous manifestations of Fabry disease: A systematic review

open access: yesThe Journal of Dermatology, Volume 52, Issue 4, Page 571-582, April 2025.
Abstract Fabry disease (FD) is a rare X‐linked lysosomal storage disorder resulting in potential debilitating accumulation of glycosphingolipids in organs such as skin, nerves, heart, kidneys, lungs, and the central nervous system. Skin is easily investigated and can guide clinicians to diagnose FD, minimizing delay of enzyme substitution therapy. This
Rami Nabil Al‐Chaer   +4 more
wiley   +1 more source

Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus [PDF]

open access: yes, 2012
Sirolimus, a potent inhibitor of B- and T-cell activation, is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance.
Barday, Z   +6 more
core   +1 more source

Real‐world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study

open access: yesBritish Journal of Haematology, Volume 206, Issue 4, Page 1246-1249, April 2025.
In this study, we collected real‐world evidence on the use of pegcetacoplan among 22 Italian patients with paroxysmal nocturnal haemoglobinuria showing suboptimal response to anti‐C5 treatments eculizumab and ravulizumab. Most patients exhibited a complete or good response as per the criteria of the European Bone Marrow Transplant group (Risitano et al.
Elisabetta Metafuni   +19 more
wiley   +1 more source

Utilizing Machine Learning to Predict Liver Allograft Fibrosis by Leveraging Clinical and Imaging Data

open access: yesClinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Background and Aim Liver transplant (LT) recipients may succumb to graft‐related pathologies, contributing to graft fibrosis (GF). Current methods to diagnose GF are limited, ranging from procedural‐related complications to low accuracy. With recent advances in machine learning (ML), we aimed to develop a noninvasive tool using demographic ...
Madhumitha Rabindranath   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy